BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16899605)

  • 21. Gene expressions associated with chemosensitivity in human hepatoma cells.
    Hoshida Y; Moriyama M; Otsuka M; Kato N; Taniguchi H; Shiratori Y; Seki N; Omata M
    Hepatogastroenterology; 2007 Mar; 54(74):489-92. PubMed ID: 17523305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma.
    Zhu H; Pei HP; Zeng S; Chen J; Shen LF; Zhong MZ; Yao RJ; Shen H
    J Proteome Res; 2009 Aug; 8(8):3969-76. PubMed ID: 19507834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise.
    Sun Z; Yang P
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2063-8. PubMed ID: 17119029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for plasma proteomic profiling of cancers.
    Omenn GS
    Proteomics; 2006 Oct; 6(20):5662-73. PubMed ID: 16991194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T; Volm M
    Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
    Nagasaki K; Miki Y
    Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis.
    Tanaka S; Sakai A; Kimura K; Yoshida H; Fushitani H; Ogata A; Miyamoto A; Fukushima M; Wada A; Tanigawa N
    Int J Oncol; 2008 Aug; 33(2):361-70. PubMed ID: 18636157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The search for optimal response prediction in cancer leads to a personalized approach.
    Van Cutsem E; Ciardiello F
    Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
    [No Abstract]   [Full Text] [Related]  

  • 30. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncoproteomics.
    Joshi S; Tiwari AK; Mondal B; Sharma A
    Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data.
    Wan P; Li Q; Larsen JE; Eklund AC; Parlesak A; Rigina O; Nielsen SJ; Björkling F; Jónsdóttir SÓ
    Bioorg Med Chem; 2012 Jan; 20(1):167-76. PubMed ID: 22154557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
    Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
    Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells.
    Chen YR; Juan HF; Huang HC; Huang HH; Lee YJ; Liao MY; Tseng CW; Lin LL; Chen JY; Wang MJ; Chen JH; Chen YJ
    J Proteome Res; 2006 Oct; 5(10):2727-42. PubMed ID: 17022644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The prediction of the individual chemosensitivity of human malignant tumors: the biological patterns and clinical results].
    Chissov VI; Sergeeva NS; Borisov VI; Skotnikova OI; Sviridova IK
    Eksp Klin Farmakol; 1995; 58(1):11-5. PubMed ID: 7787684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines.
    Takahashi T; Saikawa Y; Nakamura R; Kumagai K; Takeuchi H; Kubota T; Kitagawa Y
    Oncol Rep; 2009 Feb; 21(2):451-9. PubMed ID: 19148522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
    Pocaly M; Lagarde V; Etienne G; Dupouy M; Lapaillerie D; Claverol S; Vilain S; Bonneu M; Turcq B; Mahon FX; Pasquet JM
    Proteomics; 2008 Jun; 8(12):2394-406. PubMed ID: 18563733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.